Augmentation of 1-β-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 895-901

  Freund, A ^a   Boos, J ^a   Harkin, S ^b   Schultze Mosgau, M ^b   Veerman, G ^c   Peters, G J ^c   Gescher, A ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Antisignalling drugs; Apoptosis; Ara C; Cytotoxicity; HL 60 cells; Ribonucleotide reductase inhibitors

Indexed keywords

4,5 DIANILINOPHTHALIMIDE; CLADRIBINE; CYTARABINE; DNA; FLUDARABINE; GENISTEIN; HYDROXYUREA; NORDIHYDROGUAIARETIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; RETINOIC ACID; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; STAUROSPORINE; TYRPHOSTIN A48; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CYTARABINE; HL-60 CELLS; HUMANS; LEUKEMIA; RIBONUCLEOTIDE REDUCTASES;

EID: 0032077388     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10149-6     Document Type: Article

References (47)

1. Kufe D, Spriggs D, Egan EM, Munroe D. Relationship among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 1984, 64, 54-58.
2. Plunkett W, lacoboni S, Keating MJ. Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-β-Darabinofuranosylcytosine. Scand J Haematol 1986, 34(Suppl. 44), 51-59.
3. Boos J, Hohenlöchter B, Schulze-Westhoff P, et al. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med Pediatr Oncol 1996, 26, 397-404.
4. Zühlsdorf M, Vormoor J, Boos J. Cytosine arabinoside resistance in childhood. Leukemia (in press).
5. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia. J Clin Oncol 1993, 11, 116-124.
6. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 1996, 87, 256-264.
7. Teofili L, Pierelli L, lovino MS, et al. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leukemia Res 1992, 16, 497-503.
8. Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD. Modulation of 1-[β-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncol Res 1994, 6, 87-99.
9. Grant S, Jarvis WD, Swerdlow PS, et al. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res 1992, 52, 6270-6278.
10. Jarvis WD, Povirk LF, Turner AJ, et al. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1 [β-D-arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 1994, 47, 839-852.
11. Lishner M, Curtis JE, Minkin S, McCulloch EA. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 1989, 3, 784-788.
12. Yang GS, Minden MD, McCulloch EA. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 1993, 7, 1012-1019.
13. Kharbanda S, Emoto Y, Kisaki H, Saleem A, Kufe D. 1-β-Darabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Mol Pharmacol 1994, 46, 67-72.
14. Emoto Y, Kisaki H, Manome Y, Kharbanda S, Kufe D. Activation of protein kinase C-S in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood 1996, 87, 1990-1996.
15. lyn kinase in human myeloid leukemia cells. Biochemistry 1995, 34, 1058-1063.
16. Dou QP, An B, Yu C. Failure to dephosphorylate retinoblastoma protein in drug-resistant cells. Biochem Biophys Res Commun 1995, 214, 771-780.
17. Dou QP, Lui WYL. Activation of cyclin E-dependent kinase by DNA damage signals during apoptosis. Cancer Res 1995, 55, 5222-5225.
18. Brach MA, Kharbanda SM, Herrmann F, Kufe DW. Activation of the transcription factor NFtcB in human KG-1 myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Mol Pharmacol 1992, 41, 60-63.
19. Brach MA, Herrmann F, Kufe DW. Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood 1992, 79, 728-734.
20. Henschler R, Brennscheidt U, Mertelsmann R, Herrmann F. Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-D-arabinofuranosylcytosine. Mol Pharmacol 1991, 39, 171-176.
21. Gunji H, Kharbanda S, Kufe D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-Darabinofuranosylcytosine. Cancer Res 1991, 51, 741-743.
22. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J Biol Chem 1987, 262, 5592-5595.
23. Meggio F, Donella Deana A, Ruzzene M, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. EurJBiochem 1995, 234, 317-322.
24. Traxler P, Lydon N. Recent advances in protein tyrosine kinase inhibitors. Drugs of the Future 1995, 20, 1261-1274.
25. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989, 32, 2344-2352.
26. Domin J, Higgins T, Rozengurt E. Preferential inhibition of platelet-derived growth-factor (PDGF)-stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid. J Biol Chem 1994, 269, 8260-8267.
27. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidinekinase-deficient human promyelocytic leukemic cell line highly resistant to 1-D-arabinofuranosylcytosine. Cancer Res 1984, 44, 5029-5037.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983, 65, 55-63.
29. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47, 936-942.
30. Habtemariam S. Catechols and quercetin reduce MTT through iron ions: a possible artefact in cell viability assays. Phytother Res 1995, 9, 603-605.
31. Pagliacci MC, Spinozzi F, Migliorati G, et al. Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer 1993, 29A, 1573-1577.
32. Gorczyka W, Gong J, Ardelt B, Traganos F, Darzynkievicz Z. The cell cycle related changes in susceptibility of HL60 cells to apoptosis induced by antitumour agents. Cancer Res 1992, 52, 6270-6278.
33. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988, 48, 329-334.
34. Ruiz van Haperen VWT, Veeman G, Vermorken JB, Pinedo HM, Peters GJ. Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1996, 15, 911-918.
35. Arner ESJ, Spasukoukotskaja T, Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 1992, 188, 712-718.
36. Sorenson CM, Bertrand R, Pommier Y. Apoptosis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990, 82, 749-755.
37. Ormerod MG. Flow Cytometry - A Practical Approach. Oxford, Oxford University Press, 1990, 69-87.
38. Bhalla K, Swerdlow P, Grant S. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-D-arabinofuranosylcytosine in highly resistant human leukemia cells. Blood 1991, 78, 2937-2044.
39. Beerenbaum MC. What is synergy? Pharmacol Rev 1989, 41, 93-141.
40. Chen LL, Gansbacher B, Gilboa E, et al. Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid-induced granulocytic differentiation. Cell Growth Diff 1993, 4, 769-776.
41. Bouffard DY, Momparler RL. Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leukemia Res 1995, 19, 849-856.
42. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992, 19, 11-19.
43. Katz M, Saibil F. Herbal hepatitis: Subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol 1990, 12, 203206.
44. Meyer T, Regenass U, Fabbro D, et al. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumour activity. Int J Cancer 1989, 43, 851-856.
45. Hunakova L, Sulikova M, Duraj J, Sedlak J, Chorvath J. Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (ara-C)-induced apoptosis in multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors. Neoplasma 1996, 5, 291-295.
46. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to ara-C. Leukemia 1995, 9, 131-138.
47. Manome Y, Wen PY, Dong Y, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nature Med 1996, 2, 567-573.